Host Barriers to In Vivo HSC Gene Therapy with Helper-Dependent Adenovirus Vectors.
- 1Department of Medicine, University of Washington, Seattle, WA 98195, USA.
- 2Department of Pathology and Laboratory Medicine, University of Washington, Seattle, WA 98195, USA.
- 3State Key Laboratory of Virology and Biosafety, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan 430071, China.
Abstract
Ex vivo hematopoietic stem cell (HSC) gene therapy strategies have proved effective for the treatment of various diseases, with recent advances leading to the clinical approval of several cell products. To overcome issues associated with the cost and technical complexity of ex vivo strategies, we turn towards in vivo strategies that will allow us to avoid myeloablative transplantation and broaden access. Advances in the engineering of adenoviruses have made them a promising platform for the targeted in vivo delivery of gene therapy vectors to HSCs. This narrative review highlights host barriers to in vivo HSC gene therapy using helper-dependent adenovirus vectors including innate and adaptive immune responses in the blood, virus uptake and sequestration by non-target cells and tissues, difficulty accessing the bone marrow niche, and the inefficient targeting of quiescent HSCs. We present recent advances aimed at overcoming these barriers including immune modulation and vector engineering strategies, improved predictive models, novel HSC targeting strategies, and enrichment of modified HSCs. This forward-looking review highlights a path towards achieving the clinical translation of predictable, safe and accessible in vivo adenovirus-mediated HSC gene therapies.
Related
- Contrasting Effects of Human, Canine, and Hybrid Adenovirus Vectors on the Phenotypical and Functional Maturation of Human Dendritic Cells: Implications for Clinical Efficacy
- Porcine Adenovirus-Based Viral Vectors for Swine Vaccines: A Scoping Review and Future Perspectives.
- Stealthy lentiviral vectors: Breaking the barriers to systemic in vivo gene delivery
- In Search of Adeno-Associated Virus Vectors With Enhanced Cardiac Tropism for Gene Therapy
- CAR-T cell therapy in hematology malignancies: breaking barriers, engineering the future
BibTeX
@article{anderson2026host,
title = {{Host Barriers to In Vivo HSC Gene Therapy with Helper-Dependent Adenovirus Vectors.}},
author = {Anna K Anderson and André Lieber and Chang Li},
journal = {Viruses},
year = {2026},
month = sep,
doi = {10.3390/v18101078},
url = {https://europepmc.org/article/MED/42943998},
note = {CC BY},
}
RIS
TY - JOUR
TI - Host Barriers to In Vivo HSC Gene Therapy with Helper-Dependent Adenovirus Vectors.
AU - Anna K Anderson
AU - André Lieber
AU - Chang Li
PY - 2026
DA - 2026/09/30
JO - Viruses
DO - 10.3390/v18101078
UR - https://europepmc.org/article/MED/42943998
AB - Ex vivo hematopoietic stem cell (HSC) gene therapy strategies have proved effective for the treatment of various diseases, with recent advances leading to the clinical approval of several cell products. To overcome issues associated with the cost and technical complexity of ex vivo strategies, we turn towards in vivo strategies that will allow us to avoid myeloablative transplantation and broaden access. Advances in the engineering of adenoviruses have made them a promising platform for the targeted in vivo delivery of gene therapy vectors to HSCs. This narrative review highlights host barriers to in vivo HSC gene therapy using helper-dependent adenovirus vectors including innate and adaptive immune responses in the blood, virus uptake and sequestration by non-target cells and tissues, difficulty accessing the bone marrow niche, and the inefficient targeting of quiescent HSCs. We present recent advances aimed at overcoming these barriers including immune modulation and vector engineering strategies, improved predictive models, novel HSC targeting strategies, and enrichment of modified HSCs. This forward-looking review highlights a path towards achieving the clinical translation of predictable, safe and accessible in vivo adenovirus-mediated HSC gene therapies.
SN - 1999-4915
ER -